A new consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends screening patients with difficult-to-control type 2 diabetes for hypercortisolism. The report specifically cites Corcept Therapeutics’ CATALYST trial.
The CATALYST trial found hypercortisolism, a condition involving excess cortisol, in 24% of patients with hard-to-control type 2 diabetes.
Among patients with hypercortisolism, those treated with Corcept’s mifepristone (Korlym) had a substantial reduction in HbA1c, a key measure of blood sugar control, compared with patients who received a placebo.
The recommendation could lead to more screening and diagnoses, potentially benefiting Corcept’s cortisol-modulating therapies.